Skip to main content
SLS
NASDAQ Life Sciences

SELLAS Life Sciences Reports Strong Liquidity & Positive Clinical Progress for SLS009, Addressing Going Concern

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.23
Mkt Cap
$740.7M
52W Low
$0.952
52W High
$6.14
52W Position info
450% above low
Off High info
15% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

SLS has more than doubled off its 52-week low of $0.952.

Summary

SELLAS Life Sciences reported a strengthened cash position, including $42.6 million from recent warrant exercises, extending its operational runway beyond 12 months. The company also announced positive Phase 2a results for SLS009 in AML, leading to FDA guidance for a first-line study and a new European collaboration.


Key Events · Financing and Capital Events · SLS

  • Strengthened Liquidity Position

    The company reported $71.8 million in cash and cash equivalents as of December 31, 2025, further bolstered by $42.6 million in proceeds from warrant exercises received subsequent to year-end, providing sufficient capital to fund operations for at least the next twelve months.

  • Positive SLS009 Phase 2a Results in AML

    The Phase 2a clinical trial for SLS009 in relapsed/refractory AML met all primary endpoints, demonstrating an overall response rate (ORR) of 33% across all cohorts and significantly extended median overall survival (mOS) to 8.9 months, surpassing historical benchmarks of ~2.4 months.

  • FDA Recommends First-Line AML Study for SLS009

    Following the positive Phase 2a results, the FDA recommended advancing SLS009 into a randomized 80-patient Phase 2 clinical trial for newly diagnosed, first-line AML patients, with enrollment commencing in Q1 2026.

  • New European Collaboration for SLS009

    SELLAS entered into an agreement with IMPACT-AML, a European collaborative initiative, to conduct a clinical study evaluating SLS009, expanding patient access and supporting broader participation in Europe.


Analysis · SLS · Life Sciences

SELLAS Life Sciences Group's annual report highlights a significantly improved liquidity position, with cash and equivalents, including recent warrant exercises, projected to fund operations for over 12 months. This addresses a critical 'going concern' risk often associated with clinical-stage biopharmaceutical companies. The report also details positive Phase 2a clinical trial results for SLS009 in relapsed/refractory AML, which met all primary endpoints and received FDA guidance to advance into a first-line therapy study. This clinical progress, coupled with a new European collaboration for SLS009, represents a material advancement in the company's pipeline. While the company continues to incur net losses and faces ongoing arbitration with a partner, the strengthened financial runway and promising clinical developments are key positive takeaways for investors.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SLS was trading at $5.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $740.7M. The 52-week trading range was $0.95 to $6.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SLS - Latest Insights

SLS
Nov 18, 2026, 12:03 AM EST
Source: CNBC TV18
Importance Score:
7
Price at Filing: $17.14
Real-time Price: $17.06 info
Change: -$0.080 (-0.47%) info
Market Cap: $1.523B info
SLS
Nov 17, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.03
Real-time Price: $17.06 info
Change: -$0.970 (-5%) info
Market Cap: $1.523B info
SLS
Nov 17, 2026, 10:09 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $20.45
Real-time Price: $17.06 info
Change: -$3.39 (-17%) info
Market Cap: $1.523B info
SLS
Nov 17, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
10
Price at Filing: $8.00
Real-time Price: $17.06 info
Change: +$9.06 (+113%) info
Market Cap: $1.523B info
SLS
Nov 12, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.01
Real-time Price: $17.06 info
Change: +$9.05 (+113%) info
Market Cap: $1.523B info